Posted by Michael Wonder on 19 Aug 2021
Senhwa's silmitasertib receives US FDA fast track designation for the treatment of recurrent sonic hedgehog driven medulloblastoma
19 August 2021 - Senhwa Biosciences today announced that the US FDA has granted fast track designation for silmitasertib, a highly selective inhibitor of casein kinase 2 to treat patients with recurrent sonic hedgehog driven medulloblastoma.
Senhwa's clinical partner, the Pediatric Brain Tumor Consortium, is currently conducting a Phase I/II and surgical study of silmitasertib in both children and adults with recurrent sonic hedgehog driven medulloblastoma.
